



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dunstan et al.

Serial No.: 09/389,782

Group Art Unit No.: 1642

Filed: September 3, 1999

Examiner: Helms, L.

For: OPG Fusion Protein Compositions and Methods

Docket No.: A-604

TECH CENTER 1600/2900

APR 3 0 2001

RECEIVED

#10

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicants by the undersigned attorney/agent, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

The enclosed reference DE 196 54 610 is the equivalent to WO 97/23614, which was cited in Form PTO-1449 filed January 19, 2000.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date:

Please send all future correspondence to:

U.S. Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

April 23, 2001
Date

Signature